Compare ADMA Biologics Inc (ADMA) vs iShares Core Growth Allocation ETF (AOR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs iShares Core Growth Allocation ETF — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while iShares Core Growth Allocation ETF trades at $68.51. The key difference: iShares Core Growth Allocation ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | AOR | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $69.85 |
52-Week Low | $7.60 | $61.00 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AOR trades at $69.28, up slightly today, with a bullish technical signal driven by moving averages. The ETF recently reached a 52-week high near $67.72 (Defense World, 2026-04-19), indicating strong momentum. Key support sits at $69, with resistance at $70. A dividend of $0.52 is scheduled for July 2026, adding income appeal.
Outlook remains positive given technical strength and recent highs, but risks include underperformance versus the S&P 500 over the long term (24/7 Wall Street, 2026-05-25). The 60/40 allocation strategy faces scrutiny, requiring monitoring of rebalancing efficacy and broader market trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →
